Literature DB >> 11773560

Use of inhaled nitric oxide during interhospital transport of newborns with hypoxemic respiratory failure.

John P Kinsella1, Jeff Griebel, Jeffrey M Schmidt, Steven H Abman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11773560     DOI： 10.1542/peds.109.1.158

Source DB:  PubMed          Journal:  Pediatrics        ISSN： 0031-4005            Impact factor:   7.124


× No keyword cloud information.
  6 in total

1.  Clinical Outcomes of Critically Ill Patients Using Inhaled Nitric Oxide (iNO) during Intrahospital Transport.

Authors:  Leonid Koyfman; Omri Simchon; Anna Koyfman; Shoshana Mushaev; Benjamin F Gruenbaum; Ron Gal; Michael Friger; Natan Arotsker; Alexander Zlotnik; Moti Klein; Evgeni Brotfain
Journal:  Crit Care Res Pract       Date:  2021-05-05

Review 2.  Optimising neonatal transfer.

Authors:  A C Fenton; A Leslie; C H Skeoch
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2004-05       Impact factor: 5.747

3.  Inhaled nitric oxide therapy during the transport of neonates with persistent pulmonary hypertension or severe hypoxic respiratory failure.

Authors:  Calvin G Lowe; Johnn G Trautwein
Journal:  Eur J Pediatr       Date:  2007-01-05       Impact factor: 3.183

4.  Workplace NO and NO2 during combined treatment of infants with nasal CPAP and NO.

Authors:  Robert Lindwall; Mats E Svensson; Claes G Frostell; Staffan Eksborg; Lars E Gustafsson
Journal:  Intensive Care Med       Date:  2006-10-17       Impact factor: 17.440

Review 5.  Inhaled nitric oxide therapy in neonates and children: reaching a European consensus.

Authors:  Duncan J Macrae; David Field; Jean-Christophe Mercier; Jens Møller; Tom Stiris; Paolo Biban; Paul Cornick; Allan Goldman; Sylvia Göthberg; Lars E Gustafsson; Jürg Hammer; Per-Arne Lönnqvist; Manuel Sanchez-Luna; Gunnar Sedin; Nim Subhedar
Journal:  Intensive Care Med       Date:  2004-01-13       Impact factor: 17.440

Review 6.  Antenatal hypoxia and pulmonary vascular function and remodeling.

Authors:  Demosthenes G Papamatheakis; Arlin B Blood; Joon H Kim; Sean M Wilson
Journal:  Curr Vasc Pharmacol       Date:  2013-09       Impact factor: 2.719
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.